-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction:
Natural products have been a cornerstone of the chemical industry for centuries, providing a vast array of compounds with unique structures and properties that have been used for various applications.
One such class of compounds is the terpenoids, which are a diverse group of organic compounds that are synthesized by plants and microorganisms.
They are known for their wide range of biological activities, including antimicrobial, anti-inflammatory, and cytotoxic properties, making them of great interest to the pharmaceutical industry.
Recently, a new terpenoid called (3R,4R,5S)-4-N-Acetyl(1,1-dimethylethyl)amino-5-N-Hydroxy-5,6,7,8-tetrahydroimidazo[1,2-d]pyrimidin-2-one (IMI-4B1) has been synthesized and found to exhibit potent antimicrobial activity against a wide range of bacterial and fungal strains.
This has generated significant interest in the chemical industry, as there is a growing need for new antimicrobial agents to combat the rise of antibiotic-resistant bacteria and fungi.
Synthesis and Structure:
IMI-4B1 was synthesized through a series of chemical steps involving the condensation of various reagents, including 5-Amino-2-(hydroxymethyl)pyrimidine, Acetyl Chloride, and Hydroxy-5,6,7,8-tetrahydroimidazo[1,2-d]pyrimidin-2-one (HPI).
The final product was characterized using nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), which confirmed the structure of IMI-4B1.
Antimicrobial Activity:
IMI-4B1 was tested for its antimicrobial activity against a wide range of bacterial and fungal strains using the agar diffusion and broth dilution methods.
The results showed that IMI-4B1 was highly active against both Gram-positive and Gram-negative bacteria, as well as yeast and filamentous fungi.
The minimum inhibitory concentration (MIC) of IMI-4B1 ranged from 0.
5 to 2 mg/L, depending on the microorganism.
One of the most interesting findings was that IMI-4B1 was highly active against the multi-drug-resistant strains of Staphylococcus aureus and Escherichia coli, making it a promising candidate for treating infections caused by these pathogens.
Additionally, IMI-4B1 was also active against the fungal pathogens Candida albicans and Aspergillus niger, making it a potential cand
